Two-Year Analysis of CARTITUDE-1 Shows Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Myeloma
Updated CARTITUDE-1 data presented at ASH 2021 demonstrate a 98 percent overall response rate and…